

Daniel M Hartung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2723154/publications.pdf>

Version: 2024-02-01

86
papers

2,148
citations

236925

25
h-index

265206

42
g-index

86
all docs

86
docs citations

86
times ranked

2944
citing authors

#	ARTICLE	IF	CITATIONS
1	The Geographic Impact of Buprenorphine Expansion to Nurse Practitioner Prescribers in Oregon. <i>Journal of Rural Health</i> , 2022, 38, 112-119.	2.9	10
2	Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. <i>Pain</i> , 2022, 163, 83-90.	4.2	33
3	Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program. <i>Neurology: Clinical Practice</i> , 2022, 12, 36-42.	1.6	1
4	Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108615.	2.8	5
5	The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, 5.	2.2	0
6	Evaluation of a Medicaid performance improvement project to reduce high-dose opioid prescriptions. <i>BMC Health Services Research</i> , 2022, 22, 68.	2.2	0
7	Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications. <i>JAMA Internal Medicine</i> , 2022, 182, 206.	5.1	2
8	Commentary Article: Study Protocol for the Respond to Prevent Study: A Multi-State Randomized Controlled Trial to Improve Provision of Naloxone, Buprenorphine and Nonprescription Syringes in Community Pharmacies. <i>Substance Abuse</i> , 2022, 43, 901-905.	2.3	13
9	Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. <i>International Journal of MS Care</i> , 2022, 24, 90-97.	1.0	4
10	The Economic Burden of Multiple Sclerosis in the United States. <i>Neurology</i> , 2022, 98, .	1.1	61
11	Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021. <i>JCO Oncology Practice</i> , 2022, 18, e1574-e1586.	2.9	2
12	Exploring Patient Perceptions of Opioid Treatment Agreements in a Community Health Center Environment. <i>Pain Medicine</i> , 2021, 22, 970-978.	1.9	3
13	Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 395-399.	1.9	5
14	Decreasing Trends in Opioid Prescribing on Discharge to Hospice Care. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 1026-1033.	1.2	5
15	Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 28.	4.2	7
16	Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 856-864.	0.9	6
17	Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden. <i>Drug and Alcohol Dependence</i> , 2021, 224, 108729.	3.2	46
18	Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e237-e241.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Health economics of disease-modifying therapy for multiple sclerosis in the United States. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098703.	3.5	31
20	Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation. Journal of Addiction Medicine, 2021, 15, 130-133.	2.6	3
21	Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs. Neurology: Clinical Practice, 2021, 11, 298-303.	1.6	6
22	Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study. Journal of General Internal Medicine, 2020, 35, 3188-3196.	2.6	11
23	Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders, 2020, 45, 102404.	2.0	14
24	The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102554.	2.0	2
25	A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program data. Pharmacoepidemiology and Drug Safety, 2020, 29, 1168-1174.	1.9	3
26	Assessment of Opioid Prescribing Patterns in a Large Network of US Community Health Centers, 2009 to 2018. JAMA Network Open, 2020, 3, e2013431.	5.9	21
27	Qualitative study on the price of drugs for multiple sclerosis. Neurology, 2020, 94, e368-e375.	1.1	8
28	Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D. Diabetes Care, 2020, 43, e50-e51.	8.6	17
29	Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 450-455.e3.	1.5	9
30	Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists. Research in Social and Administrative Pharmacy, 2020, 16, 1422-1430.	3.0	16
31	Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis. Neurology, 2020, 94, e1407-e1414.	1.1	12
32	Evaluation of an Interdisciplinary Controlled Substance Review Committee on Opioid Prescribing in a Community Health Center. Pain Medicine, 2020, 21, 1840-1846.	1.9	5
33	Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis. JAMA Neurology, 2019, 76, 1285.	9.0	14
34	Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addiction Science & Clinical Practice, 2019, 14, 30.	2.6	67
35	Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. Health Affairs, 2019, 38, 303-312.	5.2	18
36	Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?. American Journal of Kidney Diseases, 2019, 74, 256-262.	1.9	12

#	ARTICLE	IF	CITATIONS
37	Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018. JAMA - Journal of the American Medical Association, 2019, 321, 607.	7.4	26
38	Pharmacist Provision of Hormonal Contraception in the Oregon Medicaid Population. Obstetrics and Gynecology, 2019, 133, 1231-1237.	2.4	42
39	Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid Costs. Obstetrics and Gynecology, 2019, 133, 1238-1246.	2.4	40
40	Elephant in the room. Annals of the Rheumatic Diseases, 2019, 78, e11-e11.	0.9	2
41	Uses of H.P. Acthar Gel in the Clinical Setting—Reply. JAMA Internal Medicine, 2018, 178, 583.	5.1	0
42	Does Prescription Opioid Shopping Increase Overdose Rates in Medicaid Beneficiaries?. Annals of Emergency Medicine, 2018, 71, 679-687.e3.	0.6	4
43	Effect of Automated Prescription Drug Monitoring Program Queries on Emergency Department Opioid Prescribing. Annals of Emergency Medicine, 2018, 71, 337-347.e6.	0.6	34
44	Effects of a prior authorization policy for extended-release/long-acting opioids on utilization and outcomes in a state Medicaid program. Addiction, 2018, 113, 1651-1660.	3.3	24
45	A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations. Addictive Behaviors, 2018, 86, 32-39.	3.0	6
46	Pharmacists' Role in Opioid Safety: A Focus Group Investigation. Pain Medicine, 2018, 19, 1799-1806.	1.9	49
47	Effect of a High Dosage Opioid Prior Authorization Policy on Prescription Opioid Use, Misuse, and Overdose Outcomes. Substance Abuse, 2018, 39, 239-246.	2.3	24
48	Variations in prescription drug monitoring program use by prescriber specialty. Journal of Substance Abuse Treatment, 2018, 94, 35-40.	2.8	19
49	Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin. JAMA Network Open, 2018, 1, e180482.	5.9	44
50	Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review. Journal of the American Pharmacists Association: JAPhA, 2018, 58, 568-576.	1.5	22
51	Impact of Hospital "Best Practice" Mandates on Prescription Opioid Dispensing After an Emergency Department Visit. Academic Emergency Medicine, 2017, 24, 905-913.	1.8	21
52	Trends and Characteristics of US Medicare Spending on Repository Corticotropin. JAMA Internal Medicine, 2017, 177, 1680.	5.1	28
53	Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program. Pharmacoepidemiology and Drug Safety, 2017, 26, 1053-1060.	1.9	19
54	Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. Neurotherapeutics, 2017, 14, 1018-1026.	4.4	72

#	ARTICLE	IF	CITATIONS
55	Interventions to Improve Pharmacological Adherence Among Adults With Psychotic Spectrum Disorders and Bipolar Disorder: A Systematic Review. <i>Psychosomatics</i> , 2017, 58, 101-112.	2.5	21
56	Building Oregon Data: Short-Term Incidence of Sequelae of Chronic Liver Disease in Medicaid Patients Infected With Hepatitis C Virus. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
57	Rural-Urban Differences in Chronic Disease and Drug Utilization in Older Oregonians. <i>Journal of Rural Health</i> , 2016, 32, 269-279.	2.9	21
58	The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program. <i>Psychiatric Services</i> , 2016, 67, 397-404.	2.0	23
59	Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients. <i>Neurology: Clinical Practice</i> , 2016, 6, 177-182.	1.6	20
60	Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 78-83.	5.0	2
61	A Chronic Opioid Therapy Dose Reduction Policy in Primary Care. <i>Substance Abuse</i> , 2016, 37, 141-147.	2.3	36
62	The cost of multiple sclerosis drugs in the US and the pharmaceutical industry. <i>Neurology</i> , 2015, 84, 2185-2192.	1.1	229
63	Changes in Long-acting β_2 -agonist Utilization After the FDA's 2010 Drug Safety Communication. <i>Clinical Therapeutics</i> , 2015, 37, 114-123.e1.	2.5	5
64	The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses. <i>JAMA Neurology</i> , 2015, 72, 739.	9.0	12
65	The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2015, 4, 21.	5.3	43
66	Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1411.	9.0	9
67	Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 87-94.	1.9	8
68	Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 113-121.	2.8	49
69	Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications. <i>Annals of Internal Medicine</i> , 2014, 160, 477.	3.9	173
70	Use of Administrative Data to Identify Off-Label Use of Second-Generation Antipsychotics in a Medicaid Population. <i>Psychiatric Services</i> , 2013, 64, 1236-1242.	2.0	10
71	Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review. <i>Annals of Internal Medicine</i> , 2013, 158, 114.	3.9	99
72	Role of practice-based research networks in comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 45-55.	1.4	14

#	ARTICLE	IF	CITATIONS
73	A pilot study evaluating alternative approaches of academic detailing in rural family practice clinics. BMC Family Practice, 2012, 13, 129.	2.9	21
74	Risk factors associated with linezolid-nonsusceptible enterococcal infections. American Journal of Infection Control, 2012, 40, 886-887.	2.3	12
75	Generic Substitution of Lamotrigine Among Medicaid Patients with Diverse Indications. CNS Drugs, 2012, 26, 707-716.	5.9	20
76	Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiology and Drug Safety, 2011, 20, 66-75.	1.9	23
77	One practice's experiment in refusing detail rep visits. Journal of Family Practice, 2011, 60, E1-6.	0.2	2
78	Effect of Drug Sample Removal on Prescribing in a Family Practice Clinic. Annals of Family Medicine, 2010, 8, 402-409.	1.9	19
79	Overview of clinical research design. American Journal of Health-System Pharmacy, 2009, 66, 398-408.	1.0	44
80	Impact of a Medicaid Copayment Policy on Prescription Drug and Health Services Utilization in a Fee-for-Service Medicaid Population. Medical Care, 2008, 46, 565-572.	2.4	54
81	Patterns of Atypical Antipsychotic Subtherapeutic Dosing Among Oregon Medicaid Patients. Journal of Clinical Psychiatry, 2008, 69, 1540-1547.	2.2	27
82	Rates of Adverse Events of Long-Acting Opioids in a State Medicaid Program. Annals of Pharmacotherapy, 2007, 41, 921-928.	1.9	54
83	An Evaluation Of Oregon's Evidence-Based Practitioner-Managed Prescription Drug Plan. Health Affairs, 2006, 25, 1423-1432.	5.2	9
84	Clinical implications of an accurate problem list on heart failure treatment. Journal of General Internal Medicine, 2005, 20, 143-147.	2.6	62
85	Risk of Hospitalization for Heart Failure Associated with Thiazolidinedione Therapy: A Medicaid Claims-Based Case-Control Study. Pharmacotherapy, 2005, 25, 1329-1336.	2.6	35
86	Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care medicaid population. Clinical Therapeutics, 2004, 26, 1518-1532.	2.5	37